Library Subscription: Guest
Critical Reviews™ in Therapeutic Drug Carrier Systems

Published 6 issues per year

ISSN Print: 0743-4863

ISSN Online: 2162-660X

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 2.7 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 3.6 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.8 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00023 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.39 SJR: 0.42 SNIP: 0.89 CiteScore™:: 5.5 H-Index: 79

Indexed in

Evaluation of Nanocarrier-Based Dry Powder Formulations for Inhalation with Special Reference to Anti-Tuberculosis Drugs

Volume 36, Issue 3, 2019, pp. 239-276
DOI: 10.1615/CritRevTherDrugCarrierSyst.2018024397
Get accessGet access

ABSTRACT

Pulmonary tuberculosis (TB) is a leading cause of death worldwide and is caused by the pathogen Mycobacterium tuberculosis (MTb). As treatment for TB, dry powders for inhalation (DPIs) are considered stable compared with nebulizers and metered dose inhalers and are suitable for high-dose formulations. Although extensive research has been done over the last two to three decades on nanocarrier-based DPIs for targeting MTb infection, none of the anti-TB DPI formulations have reached the market. Challenges in the proper assessment of nanocarrier-based DPIs due to the complexity of lungs is one of the reasons. In this review, the details of in vitro evaluation parameters of nanocarriers and nanocarrier-based DPIs along with their need and basic principles are discussed. Further, the thorough in vitro, ex vivo, and in vivo pharmacological evaluations, together with their procedures wherever required, are covered. The different evaluation parameters during process development, release specifications, and stability studies suggested by U.S. Food and Drug Administration Center for Drug Evaluation and Research to apply for new drug applications and abbreviated new drug applications of DPIs are also discussed. Lastly, the evaluation parameters for DPIs provided in European, United States, British, and Indian pharmacopeias are summarized.

CITED BY
  1. Patil Tulshidas S., Deshpande Ashwini S., Design, development, and characterisation of clofazimine-loaded mannosylated nanostructured lipid carriers: 33-Box-Behnken design approach, Materials Technology, 36, 8, 2021. Crossref

  2. Dholakia Jheel, Prabhakar Bala, Shende Pravin, Strategies for the delivery of antidiabetic drugs via intranasal route, International Journal of Pharmaceutics, 608, 2021. Crossref

  3. Patil Tulshidas S., Deshpande Ashwini S., Nanostructured lipid carrier-mediated lung targeted drug delivery system to enhance the safety and bioavailability of clofazimine, Drug Development and Industrial Pharmacy, 47, 3, 2021. Crossref

  4. Rath Goutam, Pradhan Deepak, Ghosh Goutam, Goyal Amit K., Challenges and Opportunities of Nanotechnological based Approach for the Treatment of Tuberculosis, Current Pharmaceutical Design, 27, 17, 2021. Crossref

  5. Ogienko Andrey G., Myz Svetlana A., Nefedov Andrey A., Ogienko Anna A., Adamova Tatyana P., Voronkova Olga M., Amosova Svetlana V., Trofimov Boris A., Boldyrev Vladimir V., Boldyreva Elena V., Clathrate Hydrates of Organic Solvents as Auxiliary Intermediates in Pharmaceutical Research and Development: Improving Dissolution Behaviour of a New Anti-Tuberculosis Drug, Perchlozon, Pharmaceutics, 14, 3, 2022. Crossref

  6. Sheikh Bashir A., Bhat Basharat A., Alshehri Bader, Mir Rakeeb A., Mir Wajahat R., Parry Zahoor A., Mir Manzoor A., Nano-Drug Delivery Systems: Possible End to the Rising Threats of Tuberculosis, Journal of Biomedical Nanotechnology, 17, 12, 2021. Crossref

  7. Belgamwar Veena, Bhoyar Vidyadevi, Trivedi Sagar, Patel Miral, Nanoparticles for the targeted drug delivery in lung cancer, in Photophysics and Nanophysics in Therapeutics, 2022. Crossref

  8. Fan Zi, Zhou Bo, Liu Yujia, Sun Wu, Fang Yuntao, Lu Hongguo, Chen Dongya, Lu Kuikui, Wu Xinyue, Xiao Tian, Xie Wenjing, Bian Qian, Optimization and Application of an Efficient and Stable Inhalation Exposure System for Rodents, AAPS PharmSciTech, 23, 1, 2022. Crossref

Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections Prices and Subscription Policies Begell House Contact Us Language English 中文 Русский Português German French Spain